IP Library Granted Patent US 8,221,741
Granted Patent B2
US 8,221,741 · App. 12/448,903 · Granted Jul 17, 2012

Methods for modulating inflammatory and/or immune responses

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,221,741
App. No.
12/448,903
Granted
Jul 17, 2012
Kind
B2
Abstract

The invention is directed to novel methods for modulating inflammatory and/or immune responses. Such methods utilize compositions comprising extraembryonic cells (herein referred to as EE cells) including but not limited to extraembryonic HLA-G positive cells (herein referred to as EHP cells) and amnion-derived multipotent progenitor cells (herein referred to as AMP cells); compositions comprising expanded EE cell populations, and/or cell lysates and/or conditioned media derived therefrom, alone or in combination with each other and/or in combination with various extracellular matrices and/or devices and/or other suitable active agents.

Claims (6)

1. A method for down-regulating the immune response a subject's peripheral blood mononuclear cells (PBMCs) exhibit when they are exposed to an antigen present on a transplanted tissue, the method comprising the step of contacting the subject PBMCs with a purified population of CD117-negative Amnion-derived Multipotent Progenitor (AMP) cells prior to exposure of the subject to the transplanted tissue, such that the AMP cells down-regulate the immune response exhibited by the PBMCs upon exposure to the transplanted tissue.

2. The method of claim 1 wherein the immune response is an autoimmune response.

3. The method of claim 1 wherein the immune response is an allogeneic response.

4. The method of claim 1 wherein the PBMCs are further contacted with one or more active agents.

5. The method of claim 4 wherein the one or more active agents is selected from the group consisting of a corticosteroid, a cyclosporine, a tacrolimus, a sirolimus, a methotrexate, an azathiopine, a mercatopurine, a cytotoxic antibiotic, a polyclonal antibody, a monoclonal antibody, an interferon, an opioid, a TNF binding protein, a mycophenolate, a FTY720, and another cell type.

6. The method of claim 5 wherein the monoclonal antibody is selected from the group consisting of an anti-T-cell receptor (CD23) and an anti-IL2 receptor (CD25) antibody.

Assignments (1)
CONFIRMATORY LICENSE Recorded Mar 31, 2022
From: N0VEOME BIOTHERAPEUTICS, INC.
To: UNITED STATES GOVERNMENT
Reel/Frame 059566/0789 →
Continuity (4)
Provisional Application 60880745 · Jan 17, 2007
Provisional Application 60902440 · Feb 21, 2007
Provisional Application 60997604 · Oct 4, 2007
Related Publication 20100068180A1 · Mar 18, 2010